CXCL1

Pathway Diagram

flowchart TD
    CXCL1["CXCL1"]
    style CXCL1 fill:#006494,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0
    Inflammation["Inflammation"]
    CXCL1 -->|"activates"| Inflammation
    Als["Als"]
    CXCL1 -->|"activates"| Als["@zhang2015"]
    Cancer["Cancer"]
    CXCL1 -->|"activates"| Cancer
    Nf__b["Nf-Kb"]
    CXCL1 -->|"activates"| Nf__b
    Tumor["Tumor"]
    CXCL1 -->|"expressed in"| Tumor
    Neuroinflammation["Neuroinflammation"]
    CXCL1 -->|"activates"| Neuroinflammation["@glass2010"]
    CXCL1 -->|"associated with"| Inflammation
    CXCL1 -->|"regulates"| Tumor
    Astrocytes["Astrocytes"]
    Astrocytes -->|"product of"| CXCL1["@perez-nievas2021"]
    INFLAMMATION["INFLAMMATION"]
    INFLAMMATION -->|"activates"| CXCL1
    Dolutegravir["Dolutegravir"]
    Dolutegravir -->|"upregulates"| CXCL1
    NF__B["NF-KB"]
    NF__B -->|"activates"| CXCL1
    CYTOKINES["CYTOKINES"]
    CYTOKINES -->|"activates"| CXCL1
    IL_6["IL-6"]
    IL_6 -->|"activates"| CXCL1
    TNF["TNF"]
    TNF -->|"regulates"| CXCL1
    PI3K["PI3K"]
    PI3K -->|"activates"| CXCL1
    style Inflammation fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
    style Als fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
    style Cancer fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
    style Nf__b fill:#5d4400,stroke:#4fc3f7,color:#e0e0e0
    style Tumor fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
    style Neuroinflammation fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
    style Astrocytes fill:#888,stroke:#4fc3f7,color:#e0e0e0
    style INFLAMMATION fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0
    style Dolutegravir fill:#006494,stroke:#4fc3f7,color:#e0e0e0
    style NF__B fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0
    style CYTOKINES fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0
    style IL_6 fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0
    style TNF fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0
    style PI3K fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0

Introduction

The CXCL1 gene encodes Growth-Regulated Oncogene alpha (GROα), a member of the C-X-C chemokine family. CXCL1 is a pro-inflammatory chemokine that signals through the CXCR2 receptor and plays critical roles in inflammation, immune cell recruitment, wound healing, and more recently, in the pathogenesis of neurodegenerative diseases including Alzheimer’s disease (AD) and Parkinson’s disease (PD) [1][2].^{1Chemokines in neurodegenerative disease (2010)2010 · PMID 20144998Open reference}

CXCL1 is produced by various cell types including neutrophils, macrophages, fibroblasts, endothelial cells, astrocytes, and microglia in response to inflammatory stimuli [3]. As a key chemokine, CXCL1 participates in the recruitment of immune cells to sites of inflammation and contributes to the neuroinflammatory cascade that drives neurodegeneration.

Protein Structure and Function

Protein Structure

CXCL1 is a small secreted chemokine protein:

• Signal peptide: First 21 amino acids for secretion

• Core structure: 72 amino acid mature peptide

• C-terminal domain: Contains ELR motif (Glu-Leu-Arg) essential for CXCR2 binding

• N-terminal domain: Receptor activation domain

• Three-dimensional structure: Forms homodimers and higher-order aggregates

The ELR motif (Glu-Leu-Arg) immediately preceding the CXC motif is crucial for CXCR2 receptor activation and angiogenic activity [4].

Normal Cellular Functions

CXCL1 performs several physiological functions:

1. Neutrophil Chemotaxis: Primary chemoattractant for neutrophils to sites of inflammation [5]

2. Cell Proliferation: Promotes fibroblast and keratinocyte proliferation during wound healing

3. Angiogenesis: Induces endothelial cell migration and new blood vessel formation [6]

4. Pain Modulation: Contributes to inflammatory pain through CXCR2 signaling

5. Host Defense: Part of innate immune response to bacterial infections

Signaling Pathways

CXCL1 signals through two G-protein coupled receptors:

CXCR2 (primary receptor):

• Activates Gi/o proteins → inhibition of adenylate cyclase

• Triggers PLCβ → IP3/DAG signaling

• Activates PI3K/Akt pathway

• Induces MAPK activation (ERK1/2, p38)

CXCR1 (secondary receptor):

• Similar signaling pathways to CXCR2

• Lower affinity for CXCL1 compared to CXCR2

Expression Pattern

Tissue Distribution

CXCL1 expression is inducible and context-dependent:

• Highest expression: Lung, liver, ovary, and inflammatory tissues

• Moderate expression: Brain, kidney, gastrointestinal tract

• Cell types producing CXCL1:

  • Neutrophils (primary source)

  • Macrophages and monocytes

  • Fibroblasts

  • Endothelial cells

  • Astrocytes [7]

  • Microglia [8]

  • Neurons (under certain conditions)

Brain Expression

In the central nervous system, CXCL1 is expressed by:

• Astrocytes: Major source in the brain, upregulated by IL-1β and TNF-α

• Microglia: Produces CXCL1 in response to pathological stimuli

• Neurons: Can express CXCL1 under inflammatory conditions

• Endothelial cells: Blood-brain barrier cells produce CXCL1 during inflammation

Role in Neurodegenerative Diseases

Alzheimer’s Disease

CXCL1 plays a multifaceted role in AD pathogenesis:

Amyloid-β-Induced Neuroinflammation

CXCL1 mediates β-amyloid-induced synaptic dysfunction [9]:

• Astrocytic CXCL1 is elevated in response to Aβ accumulation

• CXCL1-mediated signaling contributes to synaptic loss

• Promotes recruitment of microglia to amyloid plaques

Tau Pathology

CXCL1 directly contributes to tau pathology [10]:

• Triggers caspase-3 dependent tau cleavage

• Promotes tau truncation in neurons

• Facilitates tau spread between neurons

• Observed in aged mouse hippocampus

Neuroinflammation Amplification

CXCL1 amplifies the neuroinflammatory response in AD:

• Recruits additional immune cells to the brain

• Activates microglia in a positive feedback loop

• Contributes to chronic neuroinflammation

Parkinson’s Disease

CXCL1 is critically involved in PD pathogenesis:

Dopaminergic Neuron Vulnerability

CXCL1 contributes to dopaminergic neuron degeneration [11]:

• Elevated in the substantia nigra of PD models

• Mediates neuroinflammation in the nigrostriatal pathway

• Promotes neutrophil infiltration into the brain

Gut-Brain Axis

Recent research reveals a gut-brain connection [12]:

• Gut microbiota alterations increase CXCL1 expression

• CXCL1 elevation triggers early neuroinflammation

• Precedes dopaminergic neuron loss in mouse models

Neuroinflammation and Neutrophil Extracellular Traps

CXCL1 through CXCR2 mediates neuroinflammation [13]:

• Rotenone-induced PD models show CXCL1 elevation

• Neutrophil infiltration into the substantia nigra

• Neutrophil extracellular traps (NETs) formation

• Exacerbates neurodegeneration

Stroke and Ischemic Injury

CXCL1 plays a complex role in stroke:

• Early phase: Recruits neutrophils for debris clearance

• Late phase: May contribute to secondary neuronal damage

• Therapeutic target: CXCR2 antagonists show neuroprotective potential

Multiple Sclerosis

CXCL1 contributes to demyelination and lesion formation:

• Elevated in active MS lesions

• Recruits neutrophils to demyelinating areas

• Contributes to blood-brain barrier disruption

Interaction Network

CXCL1 interacts with various proteins and pathways:

Signaling Pathway Summary

Inflammatory stimulus (IL-1β, TNF-α, Aβ)
           ↓
    NF-κB/AP-1 activation
           ↓
    CXCL1 gene transcription
           ↓
    CXCL1 protein secretion
           ↓
    CXCR2 receptor binding (on neutrophils/microglia)
           ↓
    Gi/o protein activation
           ↓
    PLCβ → IP3/DAG → Ca²⁺ mobilization
           ↓
    PI3K/Akt and MAPK pathways
           ↓
    Cellular migration/inflammation

Therapeutic Implications

CXCR2 Antagonists

Several CXCR2 antagonists are in development:

Therapeutic Strategies

1. Neutralizing Antibodies: Anti-CXCL1 antibodies

2. Small Molecule Inhibitors: CXCR2 antagonists

3. Receptor Blockers: Decoy receptors

4. RNAi: siRNA targeting CXCL1 mRNA

Clinical Considerations

• CXCR2 blockade may increase infection risk

• Timing of intervention is critical

• Blood-brain barrier penetration is important for CNS disorders

See Also

• CXCL2 - Related chemokine

• CXCR2 - Primary receptor

• Neuroinflammation - Inflammatory mechanisms

• Microglia - Immune cells in brain

• Alzheimer’s Disease - AD overview

• Parkinson’s Disease - PD overview

• Chemokines - Chemokine family

External Links

• NCBI Gene: CXCL1

• UniProt: CXCL1

• OMIM: CXCL1

• Ensembl: CXCL1

• GeneCards: CXCL1

• PubMed: CXCL1

Biomarker Potential

CXCL1 as a Disease Biomarker

CXCL1 has emerged as a potential biomarker for neurodegenerative diseases:

Alzheimer’s Disease

• CSF levels: Elevated CXCL1 in cerebrospinal fluid of AD patients

• Blood-brain barrier permeability: Correlates with BBB disruption

• Disease progression: Higher levels associated with faster cognitive decline

Parkinson’s Disease

• Serum CXCL1: Elevated in early PD patients

• Prognostic value: Correlates with disease severity

• Gut-brain axis marker: Reflects gut microbiota alterations

Diagnostic Approaches

Animal Models

Mouse Models

Several mouse models have been used to study CXCL1 in neurodegeneration:

CXCL1 Knockout Mice

• Reduced neutrophil recruitment to brain

• Attenuated neuroinflammation in MPTP models

• Improved dopaminergic neuron survival

CXCR2 Knockout Mice

• Similar phenotypes to CXCL1 knockout

• Lack neutrophil response to injury

• Protective in stroke models

Transgenic CXCL1 Overexpression

• Spontaneous neuroinflammation

• Enhanced tau pathology

• Accelerated cognitive decline

Rat Models

• Rodent models show conserved CXCL1 function

• Similar receptor (CXCR2) structure and function

• Used in MPTP and 6-OHDA PD models

Genetics and Evolution

Gene Structure

The CXCL1 gene:

• Located on chromosome 4q21.1

• Contains 4 exons

• ~3.5 kb genomic DNA

• TATA-less promoter with NF-κB and AP-1 sites

Species Conservation

Current Research Directions

Novel Therapeutic Targets

Recent research focuses on:

1. Blood-brain barrier penetration: Developing CXCR2 antagonists that cross the BBB

2. Selective targeting: Avoiding systemic immune suppression

3. Combination therapies: CXCL1 blockade with other anti-inflammatory approaches

4. Timing optimization: Identifying critical windows for intervention

Clinical Trials

Several trials have investigated CXCR2 blockade:

• COPD trials: Danirixin (GS-5745) showed promise but limited CNS penetration

• Ulcerative colitis: Demonstrated anti-inflammatory effects

• Phase 1 safety studies: Generally well-tolerated

Future Directions

Key research priorities include:

• Developing BBB-penetrant CXCR2 antagonists

• Identifying patient subgroups who would benefit most

• Understanding CXCL1’s role in protein aggregation spread

• Exploring CXCL1 as an early biomarker

Summary

CXCL1 is a crucial pro-inflammatory chemokine that plays significant roles in neurodegenerative diseases. Through its primary receptor CXCR2, CXCL1 mediates neutrophil recruitment, microglial activation, and neuroinflammation—all key processes in Alzheimer’s disease, Parkinson’s disease, and other neurological conditions. The chemokine contributes to amyloid-β and tau pathology in AD and to dopaminergic neuron degeneration in PD. Therapeutic strategies targeting CXCL1 or its receptor represent promising approaches for neuroprotection, though challenges remain in achieving sufficient brain penetration and avoiding immunosuppression.

Additional Details

CXCL1 in Specific Brain Regions

Hippocampus

CXCL1 expression in the hippocampus:

• Dentate gyrus: High basal expression, increased in AD

• CA1 region: Vulnerable to Aβ-induced toxicity

• Subgranular zone: Neural stem cell niche modulation

Substantia Nigra

In Parkinson’s disease:

• Dopaminergic neurons: Express CXCR2

• Microglia: Primary source of CXCL1 in SN

• Neuroinflammation: CXCL1-mediated neutrophil infiltration

Cortex

• Layer-specific expression: Higher in layer VI

• Cortical neurons: CXCR2-mediated signaling

• White matter: Oligodendrocyte precursor cell recruitment

CXCL1 in Other Neurodegenerative Conditions

Amyotrophic Lateral Sclerosis (ALS)

• Elevated in ALS models and patients

• Motor neuron vulnerability: Contributes to inflammation

• Microglia-neuron crosstalk: Mediated by CXCL1

Huntington’s Disease

• Transcriptional dysregulation: CXCL1 upregulation

• Striatal medium spiny neurons: Affected by CXCL1 signaling

• Therapeutic potential: CXCR2 blockade

Frontotemporal Dementia

• Neuroinflammation component: CXCL1 involvement

• Microglial activation: Similar to AD patterns

• Tau pathology: CXCL1 contributes to progression

Biochemical Properties

Receptor Binding Kinetics

Intracellular Signaling Cascade

CXCL1 → CXCR2 → Gi/o
    ↓
抑制 Adenylate Cyclase
    ↓
降低 cAMP
    ↓
激活 PLCβ
    ↓
IP3 + DAG
    ↓
Ca²⁺ mobilization + PKC activation
    ↓
MAPK (ERK1/2, p38, JNK)
    ↓
Transcription factors (NF-κB, AP-1)
    ↓
Inflammatory gene expression

Comparative Biology

CXCL1 orthologs in different species:

• Mouse (KC/Cxcl1): 89% amino acid identity

• Rat (Cxcl1): 87% amino acid identity

• Zebrafish (Cxcl1-like): 45% identity

• Drosophila: No direct ortholog

Evolutionary Perspective

The CXC chemokine family evolved:

1. Early vertebrates: Single CXC chemokine

2. Teleost fish: Duplication events

3. Mammals: Complex family with multiple members

4. ELR motif conservation: Essential for function

Clinical Management

Patient Stratification

Potential biomarkers for CXCL1-targeted therapy:

• Serum CXCL1 levels: >100 pg/mL cutoff

• CSF CXCL1: BBB disruption marker

• Genetic variants: CXCR2 polymorphisms

Monitoring Treatment Response

• Serial CXCL1 measurement: Track changes

• Neuroimaging: MRI inflammation markers

• Clinical scales: Cognitive and motor function

Public Health Impact

• Prevalence: Indirect estimates from related conditions

• Healthcare costs: Neuroinflammation management

• Research funding: Increasing interest in chemokine biology

• Clinical trials: Multiple Phase 1/2 ongoing